Twist Bioscience Corporation (TWST) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TWST SEC filings page.
Twist Bioscience Corporation (TWST) reported $431.8M in revenue over the twelve months to Jun 30, 2026, up 19.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Twist's margin improvement is real, but fixed operating costs still absorb gross profit and keep cash generation negative.
From FY2021 to FY2025, gross margin expanded from39.1% to50.7% , meaning the business retained more gross profit from each sales dollar. Operating margin also improved from-115.4% to-36.2% , yet remains negative, so the margin gain has reduced rather than eliminated the fixed-cost burden.
The latest cash picture is less severe than the income statement: the net loss was
The balance sheet remains primarily equity-funded, with debt-to-equity at 0.4x, limiting the role of recorded debt in financing. However, the short-term cushion narrowed as current ratio fell from 4.9x in FY2024 to 3.6x in FY2025.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Twist Bioscience Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Twist Bioscience Corporation has an operating margin of -36.2%, meaning the company loses $36 on every $100 of revenue. This results in a profitability score of 23/100. This is up from -70.6% the prior year.
Twist Bioscience Corporation's revenue surged 20.3% year-over-year to $376.6M, reflecting rapid business expansion. This strong growth earns a score of 86/100.
Twist Bioscience Corporation carries a low D/E ratio of 0.36, meaning only $0.36 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.64, Twist Bioscience Corporation holds $3.64 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 85/100.
Twist Bioscience Corporation's operations used $47.6M of cash, and capex of $28.0M added to the outflow, for a free cash flow shortfall of $75.6M. This results in a cash flow score of 7/100.
Twist Bioscience Corporation posts a -16.4% return on equity (ROE), meaning it loses $16 for every $100 of shareholders' equity. This results in a returns score of 31/100. This is up from -44.2% the prior year.
Twist Bioscience Corporation scores 36.78, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.1B) relative to total liabilities ($168.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Twist Bioscience Corporation passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Twist Bioscience Corporation reported a net loss of $77.7M while operations used $47.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Twist Bioscience Corporation generated $118.4M in revenue in Q3 2026. This represents an increase of 23.2% from the same quarter a year earlier. Against the prior quarter it is up 6.9%.
Twist Bioscience Corporation's EBITDA was -$29.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.7% from the same quarter a year earlier. Against the prior quarter it is up 25.3%.
Twist Bioscience Corporation reported -$35.1M in net income in Q3 2026. This represents a decrease of 271.9% from the same quarter a year earlier. Against the prior quarter it is up 20.4%.
Twist Bioscience Corporation earned -$0.56 per diluted share (EPS) in Q3 2026. This represents a decrease of 269.7% from the same quarter a year earlier. Against the prior quarter it is up 21.1%.
Cash & Balance Sheet
Twist Bioscience Corporation recorded an outflow of $8.6M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents an increase of 18.1% from the same quarter a year earlier. Against the prior quarter it is up 66.0%.
Twist Bioscience Corporation held $117.4M in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Margins & Returns
Twist Bioscience Corporation's gross margin was 52.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
Twist Bioscience Corporation's operating margin was -30.6% in Q3 2026, reflecting core business profitability. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.8 percentage points.
Twist Bioscience Corporation's net profit margin was -29.6% in Q3 2026, showing the share of revenue converted to profit. This is down 50.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.2 percentage points.
Twist Bioscience Corporation's ROE was -7.9% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 12.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
Capital Allocation
Twist Bioscience Corporation invested $18.0M in research and development in Q3 2026. This represents a decrease of 0.1% from the same quarter a year earlier. Against the prior quarter it is down 8.5%.
Twist Bioscience Corporation invested $9.8M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 6.5% from the same quarter a year earlier. Against the prior quarter it is up 23.8%.
Not reported for Q3 2026.
TWST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q/A | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q/A | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $118.4M+23.2% | $110.7M+19.3% | $103.7M+16.9% | $99.0M+16.9% | $96.1M+17.9% | $92.8M+23.2% | $88.7M+24.1% | $84.7M+26.5% |
| Cost of Revenue | $55.9M+24.9% | $53.6M+14.6% | $49.7M+8.4% | $48.2M+3.6% | $44.8M-3.1% | $46.8M+5.3% | $45.9M+7.8% | $46.5M+9.6% |
| Gross Profit | $62.5M+21.7% | $57.1M+24.1% | $54.0M+26.0% | $50.8M+33.0% | $51.3M+45.4% | $46.0M+49.0% | $42.8M+47.9% | $38.2M+55.9% |
| R&D Expenses | $18.0M-0.1% | $19.7M-17.7% | $17.1M-19.6% | $17.0M-19.5% | $18.0M-19.7% | $23.9M-1.0% | $21.3M-7.8% | $21.1M-11.0% |
| SG&A Expenses | $80.7M+27.4% | $76.1M+19.5% | $69.7M+24.1% | $63.8M+20.0% | $63.4M+11.6% | $63.7M+14.5% | $56.2M+6.3% | $53.1M+12.1% |
| Operating Income | -$36.3M-20.5% | -$45.9M-10.4% | -$32.9M+5.0% | -$29.9M+16.9% | -$30.1M+66.1% | -$41.6M+15.0% | -$34.6M+26.3% | -$36.0M+28.1% |
| EBITDA | -$29.5M-22.7% | -$39.5M-12.2% | -$26.7M+5.5% | -$24.0M+18.4% | -$24.0M+70.2% | -$35.2M+13.4% | -$28.3M+27.2% | -$29.4M+28.8% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $143K | $24K | $29K+2800.0% |
| Income Tax | $311K+62.8% | $43K-75.4% | $253K+160.8% | $256K+366.7% | $191K0.0% | $175K-49.3% | $97K-19.2% | -$96K+56.8% |
| Net Income | -$35.1M-271.9% | -$44.0M-11.9% | -$30.5M+3.4% | -$27.1M+21.7% | $20.4M+123.8% | -$39.3M+13.5% | -$31.6M+26.5% | -$34.7M+25.1% |
| EPS (Basic) | -$0.56-264.7% | -$0.71-7.6% | -$0.50+5.7% | -$0.45+23.7% | $0.34+123.1% | -$0.66+16.5% | -$0.53+29.3% | -$0.59+27.2% |
| EPS (Diluted) | -$0.56-269.7% | -$0.71-7.6% | -$0.50+5.7% | -$0.45+23.7% | $0.33+122.4% | -$0.66+16.5% | -$0.53+29.3% | -$0.59+27.2% |
| Diluted Shares (Avg) | 62M+2.0% | 62M+3.4% | 61M+3.2% | N/A | 61M+5.2% | 60M+3.2% | 59M+2.9% | N/A |
TWST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q/A | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q/A | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $672.4M+4.5% | $676.2M+13.5% | $638.1M+4.8% | $641.9M+4.5% | $643.6M+0.9% | $595.6M-15.3% | $608.6M-17.0% | $614.3M-20.9% |
| Current Assets | $321.3M-5.4% | $323.4M-4.4% | $303.9M-12.0% | $333.0M-4.0% | $339.8M-6.1% | $338.4M-9.0% | $345.3M-11.5% | $346.8M-18.3% |
| Cash & Equivalents | $117.4M-41.7% | $122.7M-41.7% | $148.6M-32.9% | $183.0M-19.1% | $201.4M-15.8% | $210.4M-13.5% | $221.4M-16.8% | $226.3M-21.0% |
| Short-Term Investments | $49.4M0.0% | $49.0M+4.9% | $49.4M-0.1% | $49.4M-1.4% | $49.4M-1.7% | $46.7M-6.6% | $49.4M+10.1% | $50.1M+0.3% |
| Inventory | $35.2M+35.6% | $33.5M+60.7% | $32.9M+40.0% | $28.3M+17.6% | $25.9M-8.9% | $20.9M-31.3% | $23.5M-23.8% | $24.1M-24.9% |
| Accounts Receivable | $65.1M+30.5% | $64.2M+28.4% | $50.1M+27.3% | $57.0M+63.4% | $49.9M+55.9% | $49.9M+38.8% | $39.3M+11.2% | $34.9M-20.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $82.2M0.0% | $82.2M-4.2% | $82.2M-4.2% | $82.2M-4.2% | $82.2M-4.2% | $85.8M0.0% | $85.8M0.0% | $85.8M0.0% |
| Total Liabilities | $226.7M+37.1% | $221.1M+42.2% | $182.0M+19.2% | $168.9M+19.3% | $165.4M+12.5% | $155.5M+9.0% | $152.6M+6.9% | $141.6M-7.4% |
| Current Liabilities | $120.3M+38.1% | $120.0M+60.0% | $80.4M+15.5% | $91.4M+28.7% | $87.1M+18.0% | $75.0M+11.1% | $69.6M+6.8% | $71.0M-3.2% |
| Non-Current Liabilities | $106.4M+35.9% | $101.1M+25.6% | $101.5M+22.4% | $77.5M+9.7% | $78.3M+7.0% | $80.5M+7.1% | $83.0M+7.0% | $70.6M-11.3% |
| Total Equity | $445.7M-6.8% | $455.1M+3.4% | $456.1M0.0% | $473.0M+0.1% | $478.2M-2.6% | $440.1M-21.4% | $455.9M-22.7% | $472.7M-24.2% |
| Retained Earnings | -$1.4B-10.6% | -$1.4B-6.2% | -$1.4B-6.0% | -$1.3B-6.3% | -$1.3B-7.1% | -$1.3B-17.0% | -$1.3B-18.3% | -$1.2B-20.2% |
Not reported in any period shown, so not listed: Long-Term Debt.
TWST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q/A | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q/A | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1M+179.6% | -$17.6M-35.2% | -$24.8M-15.8% | -$11.8M+22.9% | -$1.4M+78.0% | -$13.0M+33.1% | -$21.4M+6.7% | -$15.3M+26.0% |
| Depreciation & Amortization | $6.8M+11.5% | $6.4M0.0% | $6.2M-2.9% | $6.0M-9.8% | $6.1M-26.5% | $6.4M-22.9% | $6.4M-21.9% | $6.7M-21.7% |
| Stock-Based Compensation | $18.2M+13.2% | $18.9M-6.8% | $13.3M+10.7% | N/A | $16.1M+16.9% | $20.3M+47.0% | $12.0M+8.8% | N/A |
| Capital Expenditures | $9.8M+6.5% | $7.9M+90.3% | $10.0M+339.8% | $12.4M+520.7% | $9.2M+849.7% | $4.1M+587.2% | $2.3M+50.6% | $2.0M-16.3% |
| Free Cash Flow | -$8.6M+18.1% | -$25.4M-48.5% | -$34.8M-46.8% | -$24.2M-39.9% | -$10.6M-43.9% | -$17.1M+14.5% | -$23.7M+3.2% | -$17.3M+25.0% |
| Investing Cash Flow | -$10.2M-8.5% | -$12.7M-791.0% | -$9.9M-546.7% | -$12.4M-865.2% | -$9.4M-1221.7% | -$1.4M+72.8% | -$1.5M-136.9% | -$1.3M+42.8% |
| Financing Cash Flow | $3.8M+107.4% | $4.1M+29.5% | $298K-98.3% | $5.6M+53.7% | $1.8M-37.2% | $3.2M+74.8% | $17.9M+1318.2% | $3.6M+720.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TWST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q/A | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q/A | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8%-0.6pp | 51.6%+2.0pp | 52.0%+3.8pp | 51.3%+6.2pp | 53.4%+10.1pp | 49.6%+8.6pp | 48.3%+7.8pp | 45.1%+8.5pp |
| Operating Margin | -30.6%+0.7pp | -41.4%+3.4pp | -31.7%+7.3pp | -30.2%+12.3pp | -31.4% | -44.8%+20.1pp | -39.1%+26.7pp | -42.5%+32.3pp |
| Net Margin | -29.6%-50.8pp | -39.8%+2.6pp | -29.4%+6.2pp | -27.4%+13.5pp | 21.2% | -42.4%+18.0pp | -35.6%+24.5pp | -40.9%+28.2pp |
| Return on Equity | -7.9%-12.1pp | -9.7%-0.7pp | -6.7%+0.2pp | -5.7%+1.6pp | 4.3%+21.7pp | -8.9%-0.8pp | -6.9%+0.4pp | -7.3%+0.1pp |
| Return on Assets | -5.2%-8.4pp | -6.5%+0.1pp | -4.8%+0.4pp | -4.2%+1.4pp | 3.2%+16.6pp | -6.6%-0.1pp | -5.2%+0.7pp | -5.6%+0.3pp |
| Current Ratio | 2.67-1.2x | 2.70-1.8x | 3.78-1.2x | 3.64-1.2x | 3.90-1.0x | 4.51-1.0x | 4.96-1.0x | 4.88-0.9x |
| Debt-to-Equity | 0.51+0.2x | 0.49+0.1x | 0.40+0.1x | 0.36+0.1x | 0.350.0x | 0.35+0.1x | 0.33+0.1x | 0.30+0.1x |
| Asset Turnover | 0.180.0x | 0.160.0x | 0.160.0x | 0.150.0x | 0.150.0x | 0.160.0x | 0.150.0x | 0.14+0.1x |
| FCF Margin | -7.3%+3.7pp | -23.0%-4.5pp | -33.6%-6.8pp | -24.5%-4.0pp | -11.0%-2.0pp | -18.5%+8.1pp | -26.7%+7.5pp | -20.4%+14.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Twist Bioscience Corporation TWST | FY2025 | $376.6M | -$77.7M | -20.6% | $11.1B | 50/100 |
| GRAIL, Inc. GRAL | FY2025 | $147.2M | -$408.4M | N/A | $6.9B | 63/100 |
| Neogen Corp NEOG | FY2026 | $870.4M | -$7.9M | -0.9% | $2.8B | 27/100 |
| Opko Health Inc. OPK | FY2025 | $606.9M | N/A | N/A | $1.2B | 40/100 |
| NeoGenomics, Inc. NEO | FY2025 | $727.3M | -$108.0M | -14.8% | $2.5B | 51/100 |
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.6B | 43/100 |
Where Twist Bioscience Corporation Ranks
Frequently Asked Questions
What is Twist Bioscience Corporation's annual revenue?
Twist Bioscience Corporation (TWST) reported $376.6M in total revenue for fiscal year 2025. This represents a 20.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Twist Bioscience Corporation's revenue growing?
Twist Bioscience Corporation (TWST) revenue grew by 20.3% year-over-year, from $313.0M to $376.6M in fiscal year 2025.
Is Twist Bioscience Corporation profitable?
No, Twist Bioscience Corporation (TWST) reported a net income of -$77.7M in fiscal year 2025, with a net profit margin of -20.6%.
What is Twist Bioscience Corporation's EBITDA?
Twist Bioscience Corporation (TWST) had EBITDA of -$111.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Twist Bioscience Corporation's gross margin?
Twist Bioscience Corporation (TWST) had a gross margin of 50.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Twist Bioscience Corporation's operating margin?
Twist Bioscience Corporation (TWST) had an operating margin of -36.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Twist Bioscience Corporation's net profit margin?
Twist Bioscience Corporation (TWST) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Twist Bioscience Corporation's return on equity (ROE)?
Twist Bioscience Corporation (TWST) has a return on equity of -16.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Twist Bioscience Corporation's free cash flow?
Twist Bioscience Corporation (TWST) recorded an outflow of $75.6M in free cash flow during fiscal year 2025. This represents a -9.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Twist Bioscience Corporation's operating cash flow?
Twist Bioscience Corporation (TWST) recorded an outflow of $47.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Twist Bioscience Corporation's total assets?
Twist Bioscience Corporation (TWST) had $641.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Twist Bioscience Corporation's capital expenditures?
Twist Bioscience Corporation (TWST) invested $28.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Twist Bioscience Corporation spend on research and development?
Twist Bioscience Corporation (TWST) invested $80.3M in research and development during fiscal year 2025.
What is Twist Bioscience Corporation's current ratio?
Twist Bioscience Corporation (TWST) had a current ratio of 3.64 as of fiscal year 2025, which is generally considered healthy.
What is Twist Bioscience Corporation's debt-to-equity ratio?
Twist Bioscience Corporation (TWST) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Twist Bioscience Corporation's return on assets (ROA)?
Twist Bioscience Corporation (TWST) had a return on assets of -12.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Twist Bioscience Corporation's P/E ratio?
Twist Bioscience Corporation (TWST) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $11.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Twist Bioscience Corporation's price-to-sales ratio?
Twist Bioscience Corporation (TWST) trades at 25.6x sales, its market capitalization divided by revenue of $431.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $11.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Twist Bioscience Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Twist Bioscience Corporation (TWST) held $232.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $47.6M over that year. Dividing the one by the other, the reported balance equals about 59 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Twist Bioscience Corporation's Altman Z-Score?
Twist Bioscience Corporation (TWST) has an Altman Z-Score of 36.78, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Twist Bioscience Corporation's Piotroski F-Score?
Twist Bioscience Corporation (TWST) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Twist Bioscience Corporation's earnings high quality?
Twist Bioscience Corporation (TWST) reported a net loss of $77.7M while operations used $47.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Twist Bioscience Corporation?
Twist Bioscience Corporation (TWST) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.